Trials / Completed
CompletedNCT01291199
Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome
Double-blind, Placebo-controlled Cross-over Study to Investigate the Effects of the Phosphodiesterase 5-inhibitor Vardenafil on Periphery Blood Flow and Clinical Symptoms of Patients With Raynaud's Syndrome
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- University of Cologne · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether vardenafil is effective in improving clinical symptoms and peripheral blood flow in patients with primary and secondary Raynaud phenomenon.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vardenafil | 10 mg p.o. bid for 6 weeks |
| DRUG | Placebo | Placebo p.o. 6 weeks bid |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2009-08-01
- Completion
- 2010-04-01
- First posted
- 2011-02-08
- Last updated
- 2011-02-08
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01291199. Inclusion in this directory is not an endorsement.